LockSeq - Enabling Routine and Streamlined gene editing outcome characterization for cell & gene therapy development and validation
| Reference number | |
| Coordinator | Countagen AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | October 2025 - May 2026 |
| Status | Completed |
| Venture | Innovative Startups |
| Call | Innovative Startups 2025 |
Important results from the project
All project goals were met, and several were exceeded. Detection sensitivity reached <1:1,000 ten times better than the 1:100 target. five pilot studies were completed with the nist genome editing consortium and the genehumdi cost network turnaround time fell by more than 50 and wp2 customer interviews produced an improved pricing model. lockseq is now commercialized with its first paying customers onboard.>
Expected long term effects
The results strengthen LockSeq´s position in gene editing outcome characterization. The commercial launch and first customer agreements support both a follow-on grant applications and an ongoing external financing round.
Approach and implementation
The project ran in two work packages as planned: WP1 (Oct 28, 2025–Feb 28, 2026) with five pilot studies through the NIST Genome Editing Consortium and GeneHumDi COST network, followed by WP2 (Mar 2–May 1, 2026) with more than 20 customer interviews to develop the business model and pricing strategy.